

NephroCare Health Services Ltd. – Target Achieved – SELL Recommendation

Dear Bajaj Capital Investors,

We are pleased to inform you that **Bajaj Capital's Research Team**—recommended stock, **NephroCare Health Services Limited (NephroPlus)** had successfully achieved our target price of 735 on 8 Sept 2026.

Notably, the **stock has significantly outperformed expectations, delivered a return of 21% in 2 months of our recommendation** (CMP is 775 as of 11 Sept 2026), significantly outperforming our envisaged 6 to 9 months investment horizon.

Investment View: we recommend that investors book profits and **SELL** all holdings of stock at **CMP of 775 as of 11 Sept 2026, implying realized gains of 21% in 2 months of recommendation**, ahead of our envisaged 6 to 9 months investment horizon.

Recommendation Timeline & Performance Summary:

1. 9 July 2026 – Initial BUY Recommendation: The BUY call was initiated at a price of 640 with a target price of 735, implying an upside potential of 15% over a 6 to 9 months investment horizon.

2. 8 Sept 2026 – Target Achieved: The stock achieved our target price of 735 on 8 Sept 2026 and delivered a return of 15% (CMP is 736 as of 8 Sept 2026) within 2 months of investment duration from our recommendation.

3. 11 Sept 2026 – Sell Recommendation (Profit Booking): We advised investors to book profits and **SELL** their entire holdings in NephroCare Health Services Limited (NephroPlus) stock at **CMP of 775 as of 11 Sept 2026, implying realized gains of 21% in 2 months of recommendation**, significantly ahead of our envisaged 6 to 9 months investment horizon.

Happy Investing!

Thank you and best regards,

On behalf of Bajaj Capital's Research Team